Videos

Michael J. Soileau, MD, discusses how to recognize when a patient has advanced Parkinson disease, what are the initial or relevant signs and symptoms of advanced disease, and how patients shift from early to intermediate and advanced disease.

John Brandsema, MD, and Julie Parsons, MD, discuss the approval of nusinersen for the treatment of spinal muscular atrophy and their personal experiences regarding drug safety and administration in patients.

Joohi Jimenez-Shahed, MD, describes the natural progression of Parkinson disease from the time of diagnosis to advanced disease.

Expert pediatric neurologists review the importance of early recognition and referral to neurologists for the diagnosis of spinal muscular atrophy and when it’s appropriate to approach treatment.

The director of the Montefiore Headache Center discussed the momentum within the migraine research community as well as some of the more notable presentations from AHS 2021.

The executive director of the LEAD Coalition calls for greater collaboration and support from government and the healthcare community in order to boost health equity.

The pediatric headache specialist at NYU Langone discussed what physicians should be aware of related to the signs and symptoms associated with pediatric migraine.

The vice president of Medical Affairs in Migraine at Impel discussed the clinical takeaways from the STOP 301 trial of intranasal DHE and the advantages that the novel formulation might offer patients with migraine.

Neurology News Network for the week ending June 26, 2021.

Elaine Wirrell, MD, provides background on fenfluramine, results from 2 clinical trials, and compares it to other treatment therapies.

Elizabeth Thiele, MD, PhD, reviews cannabidiol oral solution as treatment of seizures associated with Dravet syndrome and the safety profile and dosing associated with it.

The professor of Molecular Neuroscience at the Edmond and Lily Safra Center for Brain Sciences provided thoughts on the comfortability of prescribing aducanumab knowing its safety profile.

The clinical fellow at Massachusetts General Hospital discussed the basis of his study evaluating adult neurology trainees and their familiarity with SUDEP and its risks.

The vice president of Medical Affairs in Migraine at Impel discussed the STOP 301 trial of intranasal DHE and how the safety profile offers a positive for patients who would use the agent on-demand.

The importance of early diagnosis of Dravet syndrome as well as seizure triggers and comorbidities are discussed by key opinion leaders in the field.

The medical director of the Ohio State Sleep Medicine Institute provided insight on areas within sleep disorder care that need improvement, including the diagnostic process.

Joseph Sullivan, MD, and Elaine C. Wirrell, MD, discuss the presentation of Dravet syndrome in children.

The vice president of Medical Affairs in Migraine at Impel discussed the gaps in care that novel dihydroergotamine formulations, such as INP104, might be able to fill for patients with migraine.

Aristide Merola, MD, PhD, leads a discussion about the burden and impairment on the quality of life for patients with advanced Parkinson disease.

Experts in the field of Parkinson disease kick off a discussion about recognizing and managing the disease by defining advanced Parkinson disease.

Julie Parsons, MD, comments on the role of primary care providers and gene testing for the early diagnosis of spinal muscular atrophy.

The professor of Molecular Neuroscience at the Edmond and Lily Safra Center for Brain Sciences discussed her and her colleague’s initial response to the FDA’s approval of aducanumab.

Identifying spinal muscular atrophy through early diagnosis using prenatal and newborn screenings is discussed.

Advice to community physicians and neurologists who play a role in caring for patients with multiple sclerosis in community practices on optimizing therapy with high-efficacy and newer treatment options.

The neurologist from Cleveland Clinic provided perspective on why there is a need for continued pressure to research and understand more about COVID-19 and its association with headache.

The Distinguished Professor of Neuromuscular Disease at UNC School of Medicine spoke to the results of the phase 3 ADAPT trial, and what else he’s like to see investigated with efgartigimod.

The head of global research and executive vice president of Atara Biotherapeutics discussed the upcoming study evaluating ATA188.

Neurology News Network for the week ending June 19, 2021.

Experts in the field discuss second- and third-line treatment options for Dravet syndrome such as stiripentol and vagal nerve stimulation and the effects they’ve seen on patients.

A panel discussion on the North American Consensus statement on treating Dravet syndrome and the approved therapies like clobazam, ketogenic diets, and other first- and second-line therapies.